Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Jul 19

PMID 22808057

Citations 24

Authors

Feng Zhu

Xiao Hua Ma

Chu Qin

Lin Tao

Xin Liu

Zhe Shi

Cun Long Zhang

Chun Yan Tan

Yu Zong Chen

Yu Yang Jiang

Affiliations

Soon will be listed here.

Abstract

Due to extensive bioprospecting efforts of the past and technology factors, there have been questions about drug discovery prospect from untapped species. We analyzed recent trends of approved drugs derived from previously untapped species, which show no sign of untapped drug-productive species being near extinction and suggest high probability of deriving new drugs from new species in existing drug-productive species families and clusters. Case histories of recently approved drugs reveal useful strategies for deriving new drugs from the scaffolds and pharmacophores of the natural product leads of these untapped species. New technologies such as cryptic gene-cluster exploration may generate novel natural products with highly anticipated potential impact on drug discovery.

Citing Articles

Phytotherapy and Drugs: Can Their Interactions Increase Side Effects in Cancer Patients?.

Allegra S, De Francia S, Turco F, Bertaggia I, Chiara F, Armando T J Xenobiot. 2023; 13(1):75-89.

PMID: 36810432 PMC: 9945131. DOI: 10.3390/jox13010007.

HAS 1: A natural product from soil-isolated species with potent activity against cutaneous leishmaniasis caused by .

Awada B, Hamie M, El Hajj R, Derbaj G, Najm R, Makhoul P Front Pharmacol. 2022; 13:1023114.

PMID: 36299890 PMC: 9589300. DOI: 10.3389/fphar.2022.1023114.

as a Bio Functional Food Source: Pharmacological Potential, Anti-Inflammatory Actions and Related Molecular Mechanisms.

Phull A, Ahmed M, Park H Microorganisms. 2022; 10(2).

PMID: 35208860 PMC: 8875674. DOI: 10.3390/microorganisms10020405.

Isolation and Identification of Isocoumarin Derivatives With Specific Inhibitory Activity Against Wnt Pathway and Metabolome Characterization of .

Pellissier L, Koval A, Marcourt L, Queiroz E, Lecoultre N, Leoni S Front Chem. 2021; 9:664489.

PMID: 34458231 PMC: 8397479. DOI: 10.3389/fchem.2021.664489.

Putative role of natural products as Protein Kinase C modulator in different disease conditions.

Singh R, Kumar S, Tomar M, Verma P, Kumar A, Kumar S Daru. 2021; 29(2):397-414.

PMID: 34216003 PMC: 8602708. DOI: 10.1007/s40199-021-00401-z.

References

Tulp M, Bohlin L . Functional versus chemical diversity: is biodiversity important for drug discovery?. Trends Pharmacol Sci. 2002; 23(5):225-31. DOI: 10.1016/s0165-6147(02)02007-2. View

Piel J . Approaches to capturing and designing biologically active small molecules produced by uncultured microbes. Annu Rev Microbiol. 2011; 65:431-53. DOI: 10.1146/annurev-micro-090110-102805. View

Vesely J, Havlicek L, Strnad M, J Blow J, Donella-Deana A, Pinna L . Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 1994; 224(2):771-86. DOI: 10.1111/j.1432-1033.1994.00771.x. View

Gambacorti-Passerini C . Part I: Milestones in personalised medicine--imatinib. Lancet Oncol. 2008; 9(6):600. DOI: 10.1016/S1470-2045(08)70152-9. View

Newman D, Cragg G . Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007; 70(3):461-77. DOI: 10.1021/np068054v. View

McQuade T, Tomasselli A, Liu L, Karacostas V, Moss B, Sawyer T . A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science. 1990; 247(4941):454-6. DOI: 10.1126/science.2405486. View

Baltz R . Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol. 2008; 8(5):557-63. DOI: 10.1016/j.coph.2008.04.008. View

Dann J, Stammers D, Harris C, Arrowsmith R, Davies D, Hardy G . Human renin: a new class of inhibitors. Biochem Biophys Res Commun. 1986; 134(1):71-7. DOI: 10.1016/0006-291x(86)90528-0. View

Lydon N, Druker B . Lessons learned from the development of imatinib. Leuk Res. 2004; 28 Suppl 1:S29-38. DOI: 10.1016/j.leukres.2003.10.002. View

10.

Clardy J, Fischbach M, Walsh C . New antibiotics from bacterial natural products. Nat Biotechnol. 2006; 24(12):1541-50. DOI: 10.1038/nbt1266. View

11.

Druker B, Tamura S, Buchdunger E, Ohno S, Segal G, Fanning S . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2(5):561-6. DOI: 10.1038/nm0596-561. View

12.

Koehn F, Carter G . The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 2005; 4(3):206-20. DOI: 10.1038/nrd1657. View

13.

Chiang Y, Chang S, Oakley B, Wang C . Recent advances in awakening silent biosynthetic gene clusters and linking orphan clusters to natural products in microorganisms. Curr Opin Chem Biol. 2010; 15(1):137-43. PMC: 3117463. DOI: 10.1016/j.cbpa.2010.10.011. View

14.

Projan S . Why is big Pharma getting out of antibacterial drug discovery?. Curr Opin Microbiol. 2003; 6(5):427-30. DOI: 10.1016/j.mib.2003.08.003. View

15.

Wilkinson B, Micklefield J . Mining and engineering natural-product biosynthetic pathways. Nat Chem Biol. 2007; 3(7):379-86. DOI: 10.1038/nchembio.2007.7. View

16.

Berdy J . Bioactive microbial metabolites. J Antibiot (Tokyo). 2005; 58(1):1-26. DOI: 10.1038/ja.2005.1. View

17.

Pullen C, Schmitz P, Hoffmann D, Meurer K, Boettcher T, von Bamberg D . Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia. Phytochemistry. 2003; 62(3):377-87. DOI: 10.1016/s0031-9422(02)00550-2. View

18.

Watve M, Tickoo R, Jog M, Bhole B . How many antibiotics are produced by the genus Streptomyces?. Arch Microbiol. 2001; 176(5):386-90. DOI: 10.1007/s002030100345. View

19.

Sayers E, Barrett T, Benson D, Bryant S, Canese K, Chetvernin V . Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2008; 37(Database issue):D5-15. PMC: 2686545. DOI: 10.1093/nar/gkn741. View

20.

Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N . 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1996; 39(12):2285-92. DOI: 10.1021/jm960118j. View